Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1896-2026

Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm. Recall

Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm. Catalog Number: 1050030.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1896-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Mar 25, 2026
FDA report date
Apr 29, 2026
Quantity in commerce
1,622 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm. Catalog Number: 1050030.

Affected model & UDI checker

Search the exact identifiers published for Z-1896-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
1050030.Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm.Check source notice00801741010538
1050030Avitene Ultrafoam Microfibrillar Collagen Hemostat - 8cm x 6.25cm x 1cm.Check source noticeNot specified
FDA code information

Catalog Number: 1050030. UDI: (01)00801741010538(17)270728(10)WBJS0055. Lot Number: WBJS0055. Expiration Date: 07/28/2027

View the original FDA recall notice

Why was this product recalled?

Potential for product to contain foreign matter, confirmed to be inspect fragments.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Davol, Inc. take?

Davol, Inc. (Subsidiary of C.R. Bard, Inc.) notified consignees on about 03/25/2026 via emailed and mailed letter. Consignees were instructed to immediately discontinue use of and destroy any affected products on hand, hold in quarantine if destruction is not immediately possible, and complete and return the provided Customer Response Form. Consignees were also instructed to share the notification with anyone who needs to be aware within your organization and forwarded to any organization where affected products have been transferred. If affected product was purchased from a distributor, contact that distributor directly for further instructions and credit resolution. Distributors were instructed to immediately discontinue use of and destroy any affected products on hand, hold in quarantine if destruction is not immediately possible, and complete and return the provided Distributor Response Form. Distributors were further instructed to identify all customers within their distribution network who may have purchased any of the affected product listed in the notification and to provide a copy of the provided customer letter to all customers who may have received the affected product to advise them of this recall notification on BD s behalf. BD will issue replacement for destroyed product of the specific lot number identified above to customers that purchased the affected product directly from BD, following receipt of the completed Customer Response Form. BD will implement appropriate corrective and preventive actions, as warranted, to reduce the risk of recurrence.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology